ERBB2 and neoplasm: Figure 3 illustrates that EV and SG exhibit consistent ORRs across various studies, indicating uniform and stable receptor expressions, particularly by EV, in the treatment of advanced UC patients. Although the data for TE and DV are limited, tumor heterogeneities do not influence the ORRs in patients undergoing HER2-targeting ADC therapy (Lei et al., 2023).